GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cingulate Inc (NAS:CING) » Definitions » EBIT

Cingulate (Cingulate) EBIT : $-21.86 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cingulate EBIT?

Cingulate's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-2.95 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-21.86 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cingulate's annualized ROC % for the quarter that ended in Mar. 2024 was -234.97%. Cingulate's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -415.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cingulate's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -517.82%.


Cingulate EBIT Historical Data

The historical data trend for Cingulate's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cingulate EBIT Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
-11.65 -7.08 -20.68 -17.50 -22.76

Cingulate Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.85 -6.36 -5.75 -6.80 -2.95

Competitive Comparison of Cingulate's EBIT

For the Biotechnology subindustry, Cingulate's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cingulate's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cingulate's EV-to-EBIT falls into.



Cingulate EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cingulate  (NAS:CING) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cingulate's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-11.792 * ( 1 - 0% )/( (6.88 + 3.157)/ 2 )
=-11.792/5.0185
=-234.97 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cingulate's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-11.792/( ( (2.913 + max(-6.339, 0)) + (2.768 + max(-0.244, 0)) )/ 2 )
=-11.792/( ( 2.913 + 2.768 )/ 2 )
=-11.792/2.8405
=-415.14 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.512) - (6.258 + 0 + 0.593)
=-6.339

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.611) - (1.856 + 0 + -0.00099999999999989)
=-0.244

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cingulate's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-21.857/4.221
=-517.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cingulate EBIT Related Terms

Thank you for viewing the detailed overview of Cingulate's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cingulate (Cingulate) Business Description

Traded in Other Exchanges
N/A
Address
1901 W. 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Executives
Jennifer L. Callahan officer: Corporate Controller C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Peter J. Werth director, 10 percent owner C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Shane J. Schaffer director, 10 percent owner, officer: Chief Executive Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Craig S. Gilgallon officer: EVP & General Counsel C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Laurie Myers officer: EVP & Chief Operating Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Gregg Wm Givens director C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Scott Applebaum director C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Curtis Medeiros director 2120 COLORADO AVE., SUITE 230, SANTA MONICA CA 90404
Van Horn Louis G officer: EVP & Chief Financial Officer C/O CINGULATE THERAPEUTICS, 1901 W. 47TH PLACE, THIRD FLOOR, KANSAS CITY KS 66205
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Jeffrey X Conroy director 2372 MORSE AVE, IRVINE CA 92614
Thomas Jeffrey Hargroves director C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Raul R. Silva officer: EVP & Chief Science Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Matthew Brams officer: EVP & Chief Medical Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Fountainhead Shrugged, Llc 10 percent owner 1901 W. 47TH PLACE, #310, KANSAS CITY KS 66205